
ProKidney (PROK) | Stock Overview & Key Data
ProKidney Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $14.19 on March 13, 2023
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Dividend Information
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
ProKidney PROK | 1.81B Small-cap | 4.02% | -27.64% | 187.65% | 48.41% | 34.68% | -1.26% | -68.53% | -76.52% |
Vertex VRTX | 100.71B Large-cap | 0.77% | -14.77% | -11.32% | -17.17% | -3.70% | -18.80% | 38.72% | 44.75% |
Regeneron REGN | 61.52B Large-cap | 2.74% | 4.81% | -4.15% | -16.61% | -20.05% | -52.32% | -4.09% | -5.12% |
Adaptive ADPT | 1.99B Small-cap | -0.79% | 21.82% | 36.52% | 50.06% | 102.91% | 158.44% | 19.85% | -69.22% |
Cg Oncology CGON | 1.99B Small-cap | 2.44% | -4.98% | 2.82% | -7.12% | -11.77% | -30.96% | -27.03% | -27.03% |
Vericel VCEL | 1.83B Small-cap | -1.01% | 2.00% | -14.97% | -37.40% | -34.37% | -26.62% | 33.62% | 120.95% |
Ownership & Short Interest
ProKidney Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in ProKidney would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PROK's 52-week high and low?
- In the last 52 weeks, ProKidney reached a high of $7.13 (on July 9, 2025) and a low of $0.46 (on April 9, 2025).
- What is the market cap and P/E ratio for PROK?
- Curious about ProKidney's size and valuation? Its market capitalization stands at 1.81B. When it comes to valuation, the P/E ratio (trailing twelve months) is -3.81, and the forward P/E (looking ahead) is -4.63.
- Does PROK pay dividends? If so, what's the yield?
- Yes, ProKidney is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 305.81%, and the company has paid an average of $3.15 per share annually over the past 3 years.
- Who are ProKidney's main competitors or similar companies to consider before investing?
When looking at ProKidney, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.71B Healthcare Biotechnology -18.80% 38.72% Regeneron
REGN61.52B Healthcare Biotechnology -52.32% -4.09% Adaptive
ADPT1.99B Healthcare Biotechnology 158.44% 19.85% Cg Oncology
CGON1.99B Healthcare Biotechnology -30.96% -27.03% Vericel
VCEL1.83B Healthcare Biotechnology -26.62% 33.62% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for ProKidney Corp? (e.g., ROE, Debt/Equity)
- To get a sense of ProKidney's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -40.52%, the Debt to Equity ratio from the most recent quarter is 1.30, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for PROK?
- Looking at ProKidney's growth, its revenue over the trailing twelve months (TTM) was $527K. Compared to the same quarter last year (YoY), quarterly revenue grew by -3.91%, and quarterly earnings saw a YoY growth of N/A.
- How much of PROK stock is held by insiders and institutions?
- Wondering who owns ProKidney stock? Company insiders (like executives and directors) hold about 28.84% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 30.54%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.